{"version":"1.0","type":"link","title":"Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study.","author_name":"Gong T 외","author_url":"https://prs-insight.online/author/Gong%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/133552","thumbnail_width":1200,"thumbnail_height":630}